{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:03:00Z","timestamp":1762459380910,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["13\/12"],"award-info":[{"award-number":["13\/12"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GSC-4"],"award-info":[{"award-number":["GSC-4"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 294"],"award-info":[{"award-number":["EXC 294"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12964-016-0129-y","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T23:55:38Z","timestamp":1456271738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells"],"prefix":"10.1186","volume":"14","author":[{"given":"Sebastian","family":"Halbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gretzmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ellermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska U.","family":"W\u00f6hrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Dengjel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"129_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","volume":"131","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207\u201319.","journal-title":"Ann Intern Med"},{"key":"129_CR2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drup.2007.06.001","volume":"10","author":"A Burchert","year":"2007","unstructured":"Burchert A. Roots of imatinib resistance: a question of self-renewal? Drug Resist Updat. 2007;10:152\u201361.","journal-title":"Drug Resist Updat"},{"key":"129_CR3","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117:2562\u20139.","journal-title":"J Clin Invest"},{"key":"129_CR4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood. 2015;125:901\u20136.","journal-title":"Blood"},{"key":"129_CR5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O'Hare","year":"2011","unstructured":"O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17:212\u201321.","journal-title":"Clin Cancer Res"},{"key":"129_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","volume":"1","author":"M Sattler","year":"2002","unstructured":"Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, et al. Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell. 2002;1:479\u201392.","journal-title":"Cancer Cell"},{"key":"129_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2012.222","volume":"27","author":"FU Wohrle","year":"2013","unstructured":"Wohrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia. 2013;27:118\u201329.","journal-title":"Leukemia"},{"key":"129_CR8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1478-811X-11-30","volume":"11","author":"S Halbach","year":"2013","unstructured":"Halbach S, Rigbolt KT, Wohrle FU, Diedrich B, Gretzmeier C, Brummer T, et al. Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. Cell Commun Signal. 2013;11:30.","journal-title":"Cell Commun Signal"},{"key":"129_CR9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690\u20138.","journal-title":"Blood"},{"key":"129_CR10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","volume":"24","author":"DK Hiwase","year":"2010","unstructured":"Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia. 2010;24:771\u20138.","journal-title":"Leukemia"},{"key":"129_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-811X-7-22","volume":"7","author":"FU Wohrle","year":"2009","unstructured":"Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab\/DOS docking proteins. Cell Commun Signal. 2009;7:22.","journal-title":"Cell Commun Signal"},{"key":"129_CR12","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"129_CR13","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272\u201383.","journal-title":"Clin Cancer Res"},{"key":"129_CR14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"L Sun","year":"2003","unstructured":"Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116\u20139.","journal-title":"J Med Chem"},{"key":"129_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(02)00070-3","volume":"1","author":"LM Kelly","year":"2002","unstructured":"Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1:421\u201332.","journal-title":"Cancer Cell"},{"key":"129_CR16","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer Res. 2002;62:5995\u20138.","journal-title":"Cancer Res"},{"key":"129_CR17","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-08-2978","volume":"69","author":"T Kurosu","year":"2009","unstructured":"Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Sorafenib induces apoptosis specifically in cells expressing BCR\/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009;69:3927\u201336.","journal-title":"Cancer Res"},{"key":"129_CR18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","volume":"72","author":"M Rahmani","year":"2007","unstructured":"Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl\u2009+\u2009human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007;72:788\u201395.","journal-title":"Mol Pharmacol"},{"key":"129_CR19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"T Pemovska","year":"2015","unstructured":"Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015;519:102\u20135.","journal-title":"Nature"},{"key":"129_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-015-0190-9","volume":"8","author":"S Okabe","year":"2015","unstructured":"Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K. Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation. J Hematol Oncol. 2015;8:97.","journal-title":"J Hematol Oncol"},{"key":"129_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molcel.2013.01.037","volume":"50","author":"K Zmajkovicova","year":"2013","unstructured":"Zmajkovicova K, Jesenberger V, Catalanotti F, Baumgartner C, Reyes G, Baccarini M. MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance. Mol Cell. 2013;50:43\u201355.","journal-title":"Mol Cell"},{"key":"129_CR22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.humpath.2010.09.012","volume":"42","author":"K Aumann","year":"2011","unstructured":"Aumann K, Lassmann S, Schopflin A, May AM, Wohrle FU, Zeiser R, et al. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Hum Pathol. 2011;42:719\u201326.","journal-title":"Hum Pathol"},{"key":"129_CR23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/leu.2012.243","volume":"27","author":"C Preisinger","year":"2013","unstructured":"Preisinger C, Schwarz JP, Bleijerveld OB, Corradini E, Muller PJ, Anderson KI, et al. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Leukemia. 2013;27:743\u20136.","journal-title":"Leukemia"},{"key":"129_CR24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.ajhg.2012.08.027","volume":"91","author":"SR Twigg","year":"2012","unstructured":"Twigg SR, Lloyd D, Jenkins D, Elcioglu NE, Cooper CD, Al-Sannaa N, et al. Mutations in multidomain protein MEGF8 identify a Carpenter syndrome subtype associated with defective lateralization. Am J Hum Genet. 2012;91:897\u2013905.","journal-title":"Am J Hum Genet"},{"key":"129_CR25","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1073\/pnas.0813400106","volume":"106","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Alpert D, Francis R, Chatterjee B, Yu Q, Tansey T, et al. Massively parallel sequencing identifies the gene Megf8 with ENU-induced mutation causing heterotaxy. Proc Natl Acad Sci U S A. 2009;106:3219\u201324.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-016-0129-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T10:16:19Z","timestamp":1526638579000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biosignaling.com\/content\/14\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1186\/s12964-016-0129-y","relation":{},"ISSN":["1478-811X"],"issn-type":[{"type":"electronic","value":"1478-811X"}],"subject":[],"published":{"date-parts":[[2016,2,24]]},"article-number":"6"}}